Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Metacrine
Biotech
Equillium is no longer buying Metacrine, citing new cash
Equillium's merger with Metacrine has been terminated after a recent asset deal left the former with a sufficient amount of new cash.
Max Bayer
Dec 27, 2022 4:00pm
Equillium buys struggling Metacrine in $26M all-stock deal
Sep 7, 2022 8:45am
Regeneron researchers identify promising new NASH target
Aug 2, 2022 1:20am
Forte taps new exec amid shareholder dissent—Chutes & Ladders
Jun 10, 2022 9:30am
Metacrine lays off 50% of staff, axes more R&D to focus on IBD
Feb 11, 2022 2:22pm
Bristol Myers becomes latest victim of unforgiving NASH
Nov 18, 2021 10:40am
